Journal of Aging Research [53] E. J. Noonan, R. F. Place, S. Basak, D. Pookot, and L. C. Li, “miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells,” Oncotarget, vol. 1, no. 5, pp. 349–358, 2010. [54] X. Yang, M. Feng, X. Jiang et al., “miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A,” Genes and Development, vol. 23, no. 20, pp. 2388–2393, 2009. [55] S. Venkataraman, I. Alimova, R. Fan, P. Harris, N. Foreman, and R. Vibhakar, “MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence,” PLoS ONE, vol. 5, no. 6, Article ID e10748, 2010. [56] O. Slaby, R. Lakomy, P. Fadrus et al., “MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients,” Neoplasma, vol. 57, no. 3, pp. 264–269, 2010. [57] R. Garzon, M. Garofalo, M. P. Martelli et al., “Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3945–3950, 2008. [58] R. Menghini, V. Casagrande, M. Cardellini et al., “MicroRNA 217 modulates endothelial cell senescence via silent informa- tion regulator 1,” Circulation, vol. 120, no. 15, pp. 1524–1532, 2009. [59] W. G. Zhao, S. N. Yu, Z. H. Lu, Y. H. Ma, Y. M. Gu, and J. Chen, “The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS,” Carcinogenesis, vol. 31, no. 10, pp. 1726– 1733, 2010. [60] V. Borgdorﬀ, M. E. Lleonart, C. L. Bishop et al., “Multiple microRNAs rescue from Ras-induced senescence by inhibit- ing p21 Waf1/Cip1,” Oncogene, vol. 29, no. 15, pp. 2262– 2271, 2010. [61] P. M. Voorhoeve, C. le Sage, M. Schrier et al., “A genetic screen implicates miRNA-372 and miRNA-373 As oncogenes in testicular germ cell tumors,” Cell, vol. 124, no. 6, pp. 1169– 1181, 2006. [62] W. J. Cho, J. M. Shin, J. S. Kim et al., “MiR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2,” Molecules and Cells, vol. 28, no. 6, pp. 521–527, 2009. [63] K. H. Lee, Y. G. Goan, M. Hsiao et al., “MicroRNA-373 (miR- 373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer,” Experimental Cell Research, vol. 315, no. 15, pp. 2529–2538, 2009. [64] J. Yu, K. Ohuchida, K. Mizumoto, H. Fujita, K. Nakata, and M. Tanaka, “MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis and involved in cancer cell proliferation and invasion,” Cancer Biology and Therapy, vol. 10, no. 8, pp. 748–757, 2010. [65] T. S. Wong, X. B. Liu, B. Y. H. Wong, R. W. M. Ng, A. P. W. Yuen, and W. I. Wei, “Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue,” Clinical Cancer Research, vol. 14, no. 9, pp. 2588–2592, 2008. [66] H. Li, C. Bian, L. Liao, J. Li, and R. C. Zhao, “miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1,” Breast Cancer Research and Treatment, vol. 126, no. 3, pp. 565–575, 2010. 9 [67] F. Yang, Y. Yin, F. Wang et al., “miR-17-5p promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway,” Hepatology, vol. 51, no. 5, pp. 1614–1623, 2010. [68] T. F. F. Chow, M. Mankaruos, A. Scorilas et al., “The miR-17- 92 cluster is over expressed in and has an oncogenic eﬀect on renal cell carcinoma,” Journal of Urology, vol. 183, no. 2, pp. 743–751, 2010. [69] S. Takakura, N. Mitsutake, M. Nakashima et al., “Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells,” Cancer Science, vol. 99, no. 6, pp. 1147–1154, 2008. [70] K. W. Lai, K. X. Koh, M. Loh et al., “MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer,” European Journal of Cancer, vol. 46, no. 8, pp. 1456–1463, 2010. [71] B. S. Marasa, S. Srikantan, K. Masuda et al., “Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs,” Science Signaling, vol. 2, no. 94, p. ra69, 2009. [72] I. Satzger, A. Mattern, U. Kuettler et al., “MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma,” International Journal of Cancer, vol. 126, no. 11, pp. 2553–2562, 2010. [73] L. Scapoli, A. Palmieri, L. Lo Muzio et al., “MicroRNA expression proﬁling of oral carcinoma identiﬁes new markers of tumor progression,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 4, pp. 1229– 1234, 2010. [74] L. Zhangy, T. Dengy, X. Li et al., “microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network,” Carcinogenesis, vol. 31, no. 4, pp. 559–566, 2010. [75] L. Poliseno, L. Pitto, M. Simili et al., “The proto-oncogene LRF is under post-transcriptional control of MiR-20a: impli- cations for senescence,” PLoS ONE, vol. 3, no. 7, Article ID e2542, 2008. [76] L. Pitto, M. Rizzo, M. Simili et al., “miR-290 acts as a physiological eﬀector of senescence in mouse embryo ﬁbroblasts,” Physiological Genomics, vol. 39, no. 3, pp. 210– 218, 2009. [77] H. Liu, S. Deng, Z. Zhao et al., “Oct4 regulates the miR-302 cluster in P19 mouse embryonic carcinoma cells,” Molecular Biology Reports, vol. 38, no. 3, pp. 2155–2160, 2011. [78] R. D. Palmer, M. J. Murray, H. K. Saini et al., “Malig- nant germ cell tumors display common microRNA proﬁles resulting in global changes in expression of messenger RNA targets,” Cancer Research, vol. 70, no. 7, pp. 2911–2923, 2010. [79] L. L o´pez-Vicente, G. Armengol, B. Pons et al., “Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors,” Clinical Cancer Research, vol. 15, no. 14, pp. 4546–4553, 2009. [80] B. D. Chang, E. V. Broude, M. Dokmanovic et al., “A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents,” Cancer Research, vol. 59, no. 15, pp. 3761– 3767, 1999. [81] J. A. Ewald, J. A. Desotelle, G. Wilding, and D. F. Jarrard, “Therapy-induced senescence in cancer,” Journal of the National Cancer Institute, vol. 102, no. 20, pp. 1536–1546, 2010.